



Production of Antibodies in Chickens
Mojca Narat
Department of Animal Science, Biotechnical Faculty,
University of Ljubljana, Groblje 3, SI-1230 Dom`ale, Slovenia
Received: March 13, 2003
Accepted: June 9, 2003
Summary
Chickens, as a source of desired antibodies, represent an alternate animal system that
offers some advantages with respect to animal care, high productivity and special suitabi-
lity of avian antibodies for certain diagnostic purposes. Despite being an excellent counter-
part to mammal IgG chicken IgY antibodies still represent an underused resource. This
may be due to the lack of information concerning the possibility of production and appli-
cation of IgY or their use is being hampered by problems with keeping the chickens and
with IgY isolation. As a suggestion how to overcome IgY isolation problems a new immu-
noaffinity isolation method is presented here. The main purpose of the present work is to
provide information on developments and possibilities in the production of chicken IgY.
Polyclonal, monoclonal and recombinant forms of IgY, successfully produced so far, as
well as their applications are summarised. This article should be a contribution to the ef-
forts of the European Centre for the Validation of Alternative Methods (ECVAM), whose
main goal is to promote the scientific and regulatory acceptance of alternative methods,
which are of importance to the bioscience and which reduce, refine or replace the use of
laboratory animals.
Key words: antibodies, chicken egg yolk, chicken IgY, monoclonal antibodies, recombinant
antibodies, phage display, antibody library, transgenic chickens, immunoglobulin trans-
port
Introduction
Antibodies presently available for research, diag-
nostic and therapies are mostly mammalian monoclo-
nal or polyclonal antibodies. Antibody production re-
quires the use of laboratory animals, at least in the first
step. Traditionally, bigger animals such as horses,
sheep, pigs and also rabbits and guinea pigs, were
used for the production of polyclonal antibodies, while
mice and rats were used as a source of spleen for the
production of monoclonal antibodies. Nowadays, most
frequently chosen mammals for polyclonal and mono-
clonal antibody production are rabbits and mice, re-
spectively. Both technologies have their advantages but
also disadvantages. The major problem of monoclonal
antibody production is that some antigens are weakly
or not at all immunogenic for mice. In polyclonal anti-
body production purification of antibodies from mam-
malian blood has been found low yielding and labori-
ous in many cases. Both technologies also involve some
steps each of which causes distress to the animals in-
volved: i) the immunisation itself, ii) collecting of blood
samples and iii) bleeding (or sacrifying for spleen re-
moval), which is a prerequisite for antibody prepara-
tion. Disadvantages of the available techniques and
concern for animal rights enhance the interest in devel-
oping alternative methods for the production of anti-
bodies.
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Although the fact that immunised hens transfer
immunoglobulins from the serum to the egg yolk has
been known for over a hundred years, this alternative
possibility of producing antibodies has attracted atten-
tion only in the last decade (1–4). Techniques for the
production of chicken polyclonal, monoclonal and re-
combinant antibodies as well as techniques for their iso-
lation from different sources, manipulation and use are
completely comparable to the production of mammal
antibodies. Even more, some new techniques, limited
strictly to the chicken antibodies, were developed and
will be discussed in this paper. Although IgY technol-
ogy, as it was named by Schade et al. (2), has some dis-
advantages, it is worthy of attention since it has some
major advantages, great applications and promising fu-
ture.
In the sense of animal protection the use of chickens
for antibody production represents a refinement in that
the painful collecting of blood samples and final sacrific-
ing are replaced by collecting eggs with the synthesised
antibodies in egg yolk. Since chickens produce even
larger amounts of antibodies than laboratory rodents,
this technology also means the reduction in the number
of animals used in particular experiment.
Structure and Characteristics of
Avian IgY Versus Mammal IgG
Initially, avian serum immunoglobulins were classi-
fied as IgG-like immunoglobulins that are transferred to
the egg yolk (5). In 1969 Leslie and Clem (6) showed ex-
perimental data proving profound differences in their
structure and proposed the name IgY. Now IgY is re-
cognised as a typical low-molecular-weight (i.e. non-
-IgM) serum antibody of birds, reptiles, amphibia and
lungfish, and as an evolutionary ancestor of IgG and IgE
antibodies that are unique to mammals only (6,7).
Among all birds, chicken IgY is most frequently studied,
best described and characterised. General structure of
IgY molecule is the same as of IgG with 2 heavy (H)
chains with a molecular mass of 67–70 kDa each and
two light (L) chains with the molecular mass of 25 kDa
each (Fig. 1). The major difference is the number of con-
stant regions (C) in H chains: IgG has 3 C regions (C1 –
C3), while IgY has 4 C regions (C1 – C4). One addi-
tional C region with two corresponding carbohydrate
chains has a logical consequence in a greater molecular
mass of IgY compared to IgG i.e. 180 and 150 kDa, re-
spectively. IgY is much less flexible than IgG due to the
absence of the hinge between C1 and C2, which is a
unique mammalian feature. There are some regions in
IgY (near the boundaries of C1–C2 and C2–C3) con-
taining proline and glycine residues enabling only lim-
ited flexibility (7). IgY has isoelectric point 5.7–7.6 and is
more hydrophobic than IgG (8). Regarding the relatively
high core body temperature of chickens, which is 41 °C,
it is not surprising, that half-life time of IgY is in months
and that they retain their activity after 6 months at room
temperature or for one month at 37 °C (4).
Structure differences are reflected in different mo-
lecular and biochemical interactions. Most biological
effector functions of immunoglobulins are activated by
the Fc region (9), where the major structure difference
between IgG and IgY is located. That is why typical
IgG-Fc dependent functions are essentially different in
IgY molecule. First, IgY do not activate the complement
(10), second, IgY do not bind to protein-A and G (11,12),
third, IgY do not bind to mammalian antibodies i.e. to
rheumatoid factors (RF, an autoantibody reacting with
the Fc portion of IgG) (13,4) or to HAMA (human
anti-murine antibodies) (4), and fourth, they do not bind
to cell surface Fc receptor (14). These differences in mo-
lecular interactions bring great advantages to the appli-
cation of IgY antibodies that were successfully applied
in a variety of methods in different areas of research, di-
agnostics, medical application and biotechnology (15).
Chicken Polyclonal Antibody Production
– IgY Technology
Using chickens as the immunisation hosts brings a
number of advantages (16,2). Avian maternal serum an-
tibodies are transferred to egg yolk (5). Thus, simple col-
lection of eggs instead of invasive blood sampling and
bleeding has an advantage concerning the welfare of the
immunised animals. From the evolutionary point of
view chickens as an antibody producing animals also
have a great advantage (4). Namely, greater phylogen-
etic difference between the immunised animal and the
animal that was the source of antigen increases the im-
mune response. That is especially important when deal-
ing with highly conserved mammalian proteins (17)
such as hormones (18) or prions (19). Chicken immune
system will recognise epitopes on the mammalian pro-
tein more readily and will often detect epitopes that dif-
fer from the epitopes detected by mammals, such as
mice or rabbits. Keeping chickens as laboratory animals
is inexpensive and requires almost the same procedures
as keeping other laboratory animals. Housing conditions
dictated by some species-specific behaviour must be as-
sured as it is required by the state or international veter-
inary administrations. On principle, chickens bred for
egg production or SPF (bred for free of specific patho-
gens) can be used as well as outbred chickens. When
immunising chickens, two facts have to be considered: i)
10–15 % of outbred chickens are non-responders or
low-responders to certain antigens (such as Salmonella
pullorum bacterium, human serum albumin) (3); ii) sev-
eral chicken viral diseases may cause immunomodula-
tory effects which can interfere with antibody produc-
tion. Therefore, the use of SPF chickens is necessary at
least for the production of therapeutic antibodies (3).
Different immunisation protocols, using different adju-
vants, antigen dose and volume, route of injection, vac-
cination frequency and interval were described (3). Ba-
sically different immunising protocols for each antigen
and for each animal species have to be tested to find out
which method induces the highest serum or/and egg
yolk antibody titer. Usually 10–100 g (15,20,21) of pro-
tein antigen in final volume of 1 mL is applied intra-
muscularly in the breast muscle at two or three injection
sites of 7 to 8-week-old chicken. To avoid an eventual
local tissue reaction the Freund’s incomplete adjuvant
could be efficiently used even for the first immunisation
(instead of Freund’s complete adjuvant, which is usually
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used at that point when immunising mammals). Vacci-
nation frequency and interval depend on the immuno-
genic potential of antigen itself and on adjuvant used
(22). Often, reported interval is two to four weeks (15,
20,21). The presence of yolk antibodies should be checked
two weeks after the second immunisation. When the an-
tibody titer decreases booster immunisations can be
given during the whole laying period. A laying hen pro-
duces five to six eggs per week. Average volume of egg
yolk (15 mL) contains 50–100 mg of IgY, of which 2 to
10 % are specific antibodies (3). Compared to the pro-
duction of polyclonal antibodies in mammals, this is sig-
nificantly greater yield that only large mammals, such
as a horse, can reach. Comparison between the rabbit
and chicken polyclonal antibody production is pre-
sented in Table 1.
Egg yolk contains large amount of lipids. To avoid
problems in immunoassay isolation of IgY from the egg
yolk should be carried out as a final step of IgY technol-
ogy. Though they do not bind to protein A and G,
which is a popular method for isolation of IgG, there are
many other methods enabling a successful purification
(23–25). Frequently cited methods are affinity purifica-
tion (15,20,26), ammonium sulphate or PEG precipitation
(27,28) and many other methods have been compared
and discussed as well (4,25,27,29–33). We recommend a
new method, an immunoaffinity purification of IgY that
was developed in our laboratory and will be discussed
at the end of the article. IgY antibodies can be efficiently
conjugated by different molecules that are used for con-
jugation of mammalian antibodies such as biotin (23),
fluorescein (34) and peroxidase (35). They are sensitive
to papain and pepsin digestion, therefore Fab and Fab’
fragments can be produced (36).
IgY Application
Chicken polyclonal antibodies were produced
against a number of antigens (summarised in Table 2)
and were applied in many different methods for various
purposes (as a research, diagnostic, therapeutic reagents,
as a tool for purification or detection of antigens and as a
protective agent in passive immunization; summarised in
Table 2), where they provide an excellent alternative to
or substitution for their mammalian counterparts. IgY
was demonstrated to work in practically all tested immu-
nological methods that were traditionally developed for
mammalian IgG i.e. immunofluorescence, immuno-
enzyme techniques, immunoelectrophoresis and Western
blotting, immunohistochemistry and many others (15).
In diagnostics, when components of human serum
are to be examined, the human complement system, RF
and HAMA are major sources of interference and false
positive results in many immunoassays when mamma-
lian IgG antibodies are used as diagnostic reagents.
Since IgY do not react with mammalian IgG or comple-
ment system they offer a special advantage in these as-
says, which is reflected in great reduction of back-
ground and false results. In the last 5 years IgY were
reported to be used as successful agents for passive and
protective immunisation against gastrointestinal patho-
gens in humans and animals, as immunotherapeutic
agents against pathogens that are difficult to treat with
traditional antibiotics, as useful tool in cancer research,
diagnostics and therapy (summarised in Table 2).
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Table 1. Comparison of rabbit and chicken polyclonal antibody yield during a two-week period following the second immunisation
Rabbit Chicken
Number of animals 1 1
Method of sampling Bleeding (20 mL/week) daily collecting of eggs
Sample volume (in 2 weeks) 40 mL of blood 14 eggs = 210 mL of egg yolk*
Amount of total antibodies 200 mg 1120 mg**
Amount of specific antibodies 5 % (10 mg) 2–10 % (22.4–112 mg)
Rabbits/chicken – total*** 5–6 1
Rabbits/chicken – specific**** 2–11 1
Presence of other Ig IgM, IgA, IgE None
*average volume of egg yolk is 15 mL; **average amount of IgY is 80 mg per one egg yolk; ***No. of rabbits that produce an equal
amount of total antibodies as one chicken in a two-week period; ****No. of rabbits that produce an equal amount of specific anti-





Fig. 1. Structure of IgG and IgY
Chicken Monoclonal Antibodies
In 1975 Kohler and Milstein (81) described the
method for the production of monoclonal antibodies
(mAb). By fusion of antibody producing mouse cells
with their malignant counterparts (neoplastic B cell line)
they developed such a powerful technique that they
were awarded the Nobel Prize in Physiology and Medi-
cine in 1984. Although the continuous use of the technique
for almost over 30 years has enormously improved each
step in this technology it still has some limitations and
disadvantages. Some originate from the fact that the ma-
jority of mAbs are of mouse origin (some are of rat and
very rare of human origin). First, mammalian mAb are
not the most suitable for diagnostics when mammalian
serum components are involved; second, evolutionary
conserved antigens can be weak or not at all immuno-
gens for mammals. At least these two limitations can be
overcome by using chickens as an immunised donor of
spleen cells. The technique originally developed for the
production of mammalian mAb needed some modifica-
tions but the general idea and protocol remained the
same. The major problem was the establishment of cor-
responding fusion partner to chicken B cell that would
enable a successful fusion and HAT selection.
First chicken monoclonal antibodies (chmAb) were
reported in 1991 by Nishinaka et al. (82). They used four
TK– chicken myeloma B cell lines (R27H1-4) and pro-
duced chmAb against keyhole limpet haemocyanin. In
the process of HAT selection some HAT insensitive cells
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Table 2. Antigens used to produce specific polyclonal IgY and their applications
Antigen Application Reference
Human IL-6 RE 37
Human manose 6-phosphate/insulin-like growth factor-II receptor RE 38
Human transferin RE 39
Canine distemper virus RE 40
-subunit of hypoxia-inducible factor 1 (HIF-1) RE 15, 20
Cathepsin D RE 41
Helyobacter pylori RE 42
Cholera toxin B RE 43
Rabies virus RE 44
Sendai virus RE 45
Rabbit muscle actin RE 46
Human rotavirus RE, DE 47
Bovine growth hormone and prolactin RE, DE 14
Lactoferin RE, DE 48
Activin A RE, DE 49
Parathyroid hormone-related protein RE, DE 50
Mucin-like glycoprotein A RE, DE 51
B-casokinin 10 RE, DE 52
-subunit of insulin receptor DE 53
Toxoplasma gondii DE 54
Rat liver cytosolic casein kinase II DE 55
Chlamidiae DI 56
Newcastle disease virus DI 3
African horse sickness virus DI 57
Campylobacter fetus DI 58
Cartilage gp-39 DI 59
Hepatitis B surface antigen DI 60
Potato virus DI 60,61
Human blood antigens DI,RE 62,63
Influenza virus DI,RE 64
AsialoGM1 (T-antigen in human colorectal adenocarcinom) DI, RE 65
Calf thymus RNA polymerase II DI,RE,TE 66
Plasmid (naked) DNA DI, TE 67
E7 oncogenic protein of human papillomavirus type 16 DI, TE 68
P110 protein (antigen of human stomach cancer) DI, TE 69
Ig and blood components of several mammalian species DI, PU 3,70,71
Human -2 plasmin (its carboxy-terminal peptide) PU 72
Porcine endothelial cells TE 73
E. coli PI 24,61,74
Animal venoms (snake, viper, rattlesnake, scorpion) PI 29,75,76
Streptococcus mutans glucan binding protein B PI 77,78
Porcine epidemic diarrhea virus PI 79
Yersinia ruckeri PI 80
RE, research reagent; PU, purification of antigen; DE, detection of antigen; DI, diagnostic reagent;
TE, therapeutic reagent; PI, used for passive immunization
appeared and inhibited the initial growth of hybrids
and decreased the chances of selection of desired clones.
So the additional improvements of chicken myeloma B
cells were necessary. This was achieved by introduction
of ouabain resistance into the TK– myeloma cells. By es-
tablishing two chicken B myeloma cell lines MuH1 and
MuH4, successors of R27H1 and R27H4 respectively,
Nishinaka et al. (83) greatly increased the fusion effi-
ciency. In the last five years some useful ch mAbs were
produced (summarised in Table 3) with the greatest
achievement in 1998 and 1999 when the team of Prof.
Haruo Matsuda produced chmAbs against synthetic bo-
vine prion protein peptide (19) and against the N-termi-
nal part of human prion protein (13). They produced
chmAbs that are suitable tool for immunological and di-
agnostic analyses of prion diseases in humans and other
mammals and demonstrated how the problem of high
protein homology in mammals can be overcome by us-
ing phylogenetic distant chickens in antibody produc-
tion.
Recombinant Chicken Antibodies
from Phage Display and Library
Limitations of mAbs, particularly when used for hu-
man therapy, where human mAbs are most desirable,
dictated a new approach in the production of antibod-
ies. The polymerase chain reaction (PCR) enables rapid
cloning of particular protein genes, in this case Ig genes,
mostly those encoding variable (V) domains. The use of
surface-display vectors for displaying polypeptides (Ig
molecules or their fragments) on the surface of bacteria
and filamentous phage (now termed as phage display
technology), combined with in vitro selection technolo-
gies, enabled the synthesis and selection of tailor-made
antibodies. In fact, antibodies were the first proteins to
be displayed successfully on the surface of phage in
1990 (88). A direct application of phage technology is
cloning the Ig genes and creating an antibody library
that gives rapid access to the expressed genes. Reper-
toires may be created from Ig genes of hybridomas
(from mAbs production), or from B cells from spleen of
native or immunised donor. Compared to hybridoma
technology, many more Abs may be accessed from the
material of a single donor. The selected Abs have higher
affinity than mAb and can be rapidly produced in higher
amounts. Nowadays phage displayed active antibody
fragments (Fab, variable fragment Fv, single chain vari-
able fragment scFv and construct, which use two differ-
ent polypeptide chains, VH1–VH2 and VL1–VL2, known as
diabody fragments) of mouse and human origin are
routinely produced and used as well as Ig libraries from
a variety of species (89). Both technologies, phage dis-
play and construction of antibody library were also used
for the production of chicken antibodies or their frag-
ments (Table 4). Chickens offer two advantages: first,
they respond to evolutionary conserved mammalian
proteins used as antigens; second, formation of immu-
noglobulin repertoire in chickens is different from mam-
mals, which enables slightly easier manipulation. Molec-
ular diversification of Ig in mammals occurs through the
somatic recombination of a diverse set of Ig variable (V),
diversity (D) and joining (J) gene segments for heavy
and light chains (90). In chickens, single functional Ig V
and J gene segments of heavy and light chain (each) un-
dergo V(D)J rearrangement and further diversity is
achieved by gene conversions i.e. by transplanting blocks
of sequences from upstream pseudogenes in both heavy
and light chain V regions (91). This greatly simplifies
the representative amplification of V region genes since
only two pairs of primers are needed. Daves et al. (92)
first demonstrated feasibility of generating chicken
phage antibodies. They constructed the scFv library us-
ing total RNA from bursal lymphocytes of unimmuni-
sed chicken and selected by display technique phage
with specific scFv for different antigens. Yamanaka et al.
(93) constructed the library from RNA extracted from
spleen cells isolated from the chicken that was immu-
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Table 3. Chicken monoclonal antibodies produced so far
Antigen Fusion partner Application Reference
Keyhole limpet haemocyanin R27H1-4 RE 82
Hanganutziu-Deicher (HD) antigen R27H4 DI 84, 85
Eimeria acervulina R27H4 DE, RE 21, 86, 87
Human IgG MuH1, MuH4 RE 83
Bovine prion protein peptide B204 MuH1 RE, DE, DI 19
Human prion protein peptide H25 MuH1 RE, DE, DI 21
RE, research reagent; DE, detection of antigen; DI, diagnostic reagent
Table 4. Chicken recombinant antibodies generated by phage display or Ig library
Source of RNA/ Ag* Fragment Application Reference
Bursal lymphocytes/ 0 scFv ME, RE 92
Spleen cells/murine serum albumin scFv ME, RE 93
Hybridoma cells/N-terminal PrP scFv RE, DE 94
Hybridoma cells/Eimeria acerulina scFv ME, RE, DT 95-97
Spleen cells + bone marrow/ hapten fluorescein scFv, diabody, chicken/
human chimeric Fab
ME 98
*cells that were used for RNA extraction / antigen that was used for immunisation or hybridoma cells that
are specific for; ME, introduction of methodology; RE, research; DE, protein (antigen) detection; DI, dia-
gnostic reagent
nised with murine serum albumin and selected antigen-
-specific scFv by panning. Many authors reported that
hybridoma cells produce too low levels of antibodies
(94–97). In order to produce larger amount of mAbs Na-
kamura et al. (94) generated scFv using phage display.
The source of RNA were chicken hybridoma cells secret-
ing mAbs to the N-terminal part of mammalian prion
protein (PrP). Low yield in hybridoma produced mAbs
was also the main reason why Kim et al. (95), Min et al.
(96) and Song et al. (97) produced scFv antibodies from
VH and VL genes of hybridomas producing mAbs spe-
cific for different proteins of Eimeria acervulina. Perhaps
the major contribution to the development of chicken re-
combinant antibodies in last few years was made by
Andis-Windhoph et al. (98), who demonstrated the se-
lection of antigen-specific clones from three libraries
constructed from the same animal. They combined the
spleen cells and bone marrow, extracted RNA and con-
structed two scFv libraries, one for monomeric scFv and
the other for diabody formation. The third library was
chicken-human chimeric Fab antibody library, where
they also demonstrated the improvement of technique
by using a new variant of the pComb3 phage display
vector system. They developed the methodology that
would produce specific chicken antibodies for clinically
relevant antigens.
Expression of Genetically Engineered
Antibodies in Chicken Eggs
Although the recombinant antibodies revolutionised
the production of therapeutic antibodies, the need for
inexpensive and efficient production still persists.
Chicken eggs have long been recognised as a potential
source of pharmaceutical product and represent a low
cost, high-yield bioreactor system. Egg white and egg
yolk are sterile, their proteins can be fractionated with
different technologies and combined with the egg indus-
try’s capacity to produce thousands of eggs per day.
Thus, large quantities of proteins can be obtained. Nu-
merous proteins are secreted into the egg white or egg
yolk and different strategies have been used to develop
transgenic chickens which would produce eggs contain-
ing new drugs to treat serious diseases including cancer.
Recombinant human antibodies are one of these promis-
ing drugs that were demonstrated to be successfully
produced through chickens. As the chicken oocyte de-
velops, receptors on its membrane sequester large
amounts of maternal serum IgY into the egg yolk. Sherie
et al. (99) described the sequences in IgY that are impor-
tant for such receptor-mediated transport and demon-
strated why only some Ig can be transported into the
egg yolk. Namely, human IgG and IgA that were trans-
ported to egg yolk possess the corresponding sequences
(or their homologues), while chicken IgA, IgM and the
truncated form of duck IgY that was not transported
through the yolk sac membrane lack such sequences.
Their results offer the possibility to direct the deposition
of other therapeutically useful proteins into the egg yolk
and are also in agreement with the results described
four years earlier by Mohammed et al. (100). They in-
jected intravenously human IgG and human IgA into
the hens and both molecules were detected in egg yolk.
As with chicken IgA, human IgA was deposited into
egg white. A second approach that Mohammed et al.
(100) presented is the establishment of transgenic chick-
ens using stably transfected DT40 cell lines that secrete
recombinant human IgG (rhIgG) and IgA (rhIgA). Intra-
venously injected cells colonised the chicken host, and
the secreted rhIgG and rhIgA were deposited into the
egg yolk. The major disadvantage of this approach,
which is not tolerable, is that rhIgG and rhIgA elicited a
chicken anti-human immune response, therefore a ma-
jority of egg yolk antibodies would be anti-rhIgG/A
IgY. In conclusion they suggest that by suppressing the
expression of endogenous chicken Ig, it would be possi-
ble to generate transgenic hens that deposit mg amounts
of a single defined rhAb.
Immunoafinity IgY Isolation
Avian technology has many advantages over the ge-
netic modification of mammals, who were developed to
produce drugs in their milk, and certainly has a great
future. Chicken eggs can be produced fast, with low
cost and high yield and long term production can be
achieved. That is why several avian transgenic compa-
nies entered the scene. Though the oral administration
of specific antibodies by eating eggs is an attractive ap-
proach to establish protective immunity against gastro-
intestinal pathogens and is becoming more and more in-
teresting as increasing number of antibiotic resistant
bacteria develops, the deficiency of this approach is in
the great reduction of IgY antibody activity in gastroin-
testinal tract under acidic conditions. To overcome this
problem the liposomal encapsulation of IgY was pro-
posed by Shimizu et al. (101). For this purpose and for
all technologies described above, IgY isolation as a final
step is required. To optimise the isolation of IgY from
all sources, either egg yolk, chicken serum, hybridoma
culture supernatant or bacterial cell lysat, immunoaffi-
nity isolation method was developed in our laboratory.
Mouse anti chicken IgY mAbsM2, specific for H chain,
were produced (102) and coupled with CNBr activated
Sepharose 4B according to the producer’s manuals
(Sigma). Chicken serum IgY, egg yolk IgY (after lipid
elimination) and IgY from hybridoma culture superna-
tant were applied to the column and after washing with
PBS (pH=8), pH conditions were gradually decreased
(pH=4; 3.5; 3; 2.5; 2). As it was demonstrated by dot
immunobinding assay (DIBA) (103) IgY were eluted at
pH=3 and 2.5 (Fig. 2).
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Fig. 2. Immunoafinity isolation of IgY on M2-CNBr activated
Sepharose 4B and results of DIBA
Clone 1F5/3G2 that produces mAbM2 is stable, so
mAbs can be produced at any time. M2 themselves, sol-
uble or bound to CNBr activated Sepharose, are highly
stable as well, so after regeneration the column can be
used many times. Except for egg yolk, where the first
step is lipid removal, this is very fast and standardised,
one-step method that could substitute many different less
specific biochemical methods for IgY isolation, which
still remains a necessary step for the successful applica-
tion.
In conclusion, it should be pointed out that scien-
tists working with antibodies, either producing or using
them, could take into consideration alternative methods
instead of the production of antibodies in mammals. Be-
side that, producing IgY in chickens could sometimes be
even more successful than producing mammalian IgG,
this alternative method is in agreement with interna-
tional effort to reduce, refine and if possible, to replace
animals in experimentation (104).
References
1. R. Schade, C. Pfister, R. Halatsch, P. Henklein, ATLA
Altern. Lab. Anim. 19 (1991) 403–419.
2. R. Schade, P. Henklein, A. Hlinak: Egg yolk antibody: sta-
te of the art and advantageous use in the life sciences. In:
Animal Alternatives, Welfare and Ethics, L.F.M. Zutphen, M.
Balls (Eds.), Elsevier, Amsterdam (1997) pp. 973–981.
3. R. Schade, C. Staak, C. Hendriksen, M. Erhard, H. Hugl,
G. Koch, A. Larsson, W. Pollmann, M. van Regenmortel,
E. Rijke, H. Spielmann, H. Steinbuch, D. Straughan, ATLA
Altern. Lab. Anim. 24 (1996) 925–934.
4. A. Larson, R-M. Bålöw, T. Lindhal, P-O. Forsberg, Poultry
Sci. 72 (1993) 1807–1812.
5. F. Klemperer, Arch. Exp. Pathol. Pharmacol. 31 (1893)
356–382.
6. G. A. Leslie, L. W. Clem, J. Exp. Med. 130 (1969) 1337–1352.
7. G. W. Warr, K. E. Magor, D. A. Higgins, Immunol. Today,
16 (1995) 392–398.
8. L. Davalos, J. L. Ortega-Vinuesa, D. Bastos-Gonzales, R.
Hidalgo-Alvarez, J. Biomater. Sci. Polymer Edn. 11 (2000)
657–673.
9. J. L. Winkelhake, Immunochemistry, 15 (1978) 695–714.
10. A. Larson, P. E. Wejaker, P. O. Forsberg, T. Lindahl, J.
Immunol. Methods, 156 (1992) 79–83.
11. G. Kronwall, U. S. Seal, S. Svensson, R. C. Jr Williams,
Acta Path. Microbiol. Scand. Section B, 82 (1974) 12–15.
12. B. Åkerström, Th. Brodin, K. Reis, L. Börg, J. Immonol. 135
(1985) 2589–2592.
13. A. Larsson, J. Sjöquist, J. Immunol. Methods, 108 (1988)
205–208.
14. P. Schmidt, M. H. Erhard, D. Schmas, A. Hafner, S. Folger,
U. Losch, J. Histochem. Cytochem. 41 (1993) 1441–1446.
15. M. Tini, U. R. Jewell, G. Camenisch, D. Chilov, M. Ga-
ssmann, Comp. Biochem. Physiol.-Part A: Moll. Integrative
Physiol. 131 (2002) 569–574.
16. R. Schade, A. Hlinak, A. Marburger, P. Henklein, R. Mor-
genstern, P. Blankenstein, M. Gerl, A. Zott, C. Pfister, M.
Erhard, ATLA Altern. Lab. Anim. 25 (1997) 555–586.
17. M. Gassmann, T. Weiser, U. Hübscher, FASEB J. 4 (1990)
2528–2532.
18. T. J. Rosol, C. L. Steinmeyer, L. K. McCauley, J. I.
Merryman, J. R. Werkmeister, A. Gröne, M. T. Weckmann,
D. E. Swayne, C. C. Capen, Vet. Immunol. Immunopathol. 35
(1993) 321–337.
19. K. Matsushita, H. Horiuchi, S. Furusawa, M. Horiuchi, M.
Shinagawa, H. Matsuda, J. Vet. Med. Sci. 60 (1998) 777–779.
20. G. Camenisch, M. Tini, D. Chilow, I. Kvietikova, V. Srini-
vas, J. Caro, P. Spielmann, R. H. Wenger, M. Gassmann,
FASEB J. 13 (1999) 81–88.
21. H. Matsuda, H. Mitsuda, N. Nakamura, S. Furusawa, S.
Mohri, T. Kitamoto, FEMS Immunol. Med. Microbiol. 23
(1999) 89–194.
22. C. Schwarzkopf, B. Thiele: Chicken IgY: efficacy of alter-
native adjuvants compared to CFA. In: Animal Alternatives,
Welfare and Ethics, L. F. M. Zutphen, M. Balls (Eds.), Else-
vier, Amsterdam (1997) pp. 983–988.
23. C. Schwarzkopf, B. Thiele, ALTEX, 13 (1996) 35–39.
24. E. M. Akita, S. Nakai, J. Immunol. Methods, 160 (1993)
207–214.
25. M. Fisher, A Hlinak, T. Montag, M. Claros, R. Shade, D.
Ebner, Tierärztl. Prax. 24 (1996) 411–418.
26. D. Chilow, G. Camenisch, M. Tini, P. Spielmann, M. Ga-
ssmann: Chicken egg yolk IgY – an alternative to mamma-
lian antibodies. In: Progress in the Reduction, Refinment and
Replacement of Animal Experimentation, M. Balls, A. M. van
Zeller, M. E. Halder (Eds.), Elsevier, Amesterdam (2000)
pp. 865–872.
27. C. Maya Devi, M. Vasantha Bai, A. Vijayan Lal, P. R.
Umashankar, L. K. Krishnan, J. Biochem. Biophys. Methods,
51 (2002) 129–138.
28. A. Polson, Immunol. Invest. 19 (1990) 253–258.
29. C. Maya Devi, M. Vasantha Bai, L. K. Krishnan, Toxicon,
40 (2002) 857–861.
30. P. Hansen, J. A. Scoble, B. Hanson, N. J. Hoogenraad, J.
Immunol. Methods, 215 (1998) 1–7.
31. J. Stalberg, A. Larsson, Upsala J. Med. Sci. 106 (2001)
99–110.
32. H. M. Chang, T. C. Lu, C. C. Chen, Y. Y. Tu, J. Y. Hwang,
J. Agric. Food Chem. 48 (2000) 995–999.
33. A. Verdoliva, G. Basile, G. Fassina, J. Chromatogr. B: Bio-
med. Sci. Appl. 749 (2000) 233–242.
34. T. H. Lundahl, T. L. Lindahl, I. H. Fagerberg, N. Egberg,
A. Bunescu, A. Larsson, Blood Coagul. Fibrynol. 7 (1996)
218–220.
35. A. Larsson, A. Karlsson-Parra, J. Sjöquist, Clin. Chem. 37
(1991) 411–414.
36. E. M. Akita, S. Nakai, J. Immunol. Methods, 162 (1993)
155–164.
37. J. A. Woolly, J. London, J. Immunol. Methods, 178 (1995)
253–265.
38. G. J. Lemamy, P. Roger, J. C. Mani, M. Robert, H. Roche-
fort, J. P. Broullet, Int. J. Cancer, 80 (1999) 179–195.
39. V. Ntakarutimana, P. Demeds, M. Van Sande, S. Scharpe,
J. Immunol. Methods, 153 (1992) 133–140.
40. P. Schmidt, A. Hafner, G. H. Reubel, R. Wanke, V. Franke,
U. Losch, E. Dahme, Zbl. Veterinarmed. B, 36 (1998)
661–668.
41. P. H. Fortgens, C. Dennison, E. Elliot, Immunopharmaco-
logy, 36 (1997) 305–311.
42. K. A. Lee, S. K. Chang, Y. J. Lee, J. H. Lee, N. S. Koo, J.
Biochem. Mol. Biol. 35 (2002) 488–493.
43. G. P. Hedlund, J. Hau, In Vivo, 15 (2001) 381–384.
44. S. Sun, W. Mo,. Y. Ji, S. Liu, Rapid Commun. Mass Spectro-
metry: RCM, 15 (2001) 708–712.
45. G. Bizharov, G. Vyshniauskia, Vet. Res. Commun. 24 (2000)
103–113.
46. M. Schrader, C. J. Temm-Grove, J. L. Lessard, B. M. Joc-
kusch, Eur. J. Cell Biol. 63 (1994) 326–335.
47. H. Hatta, K. Tsuda, S. Akachi, M. Kim, T. Yamamoto, Bio-
sci. Biotechnol. Biochem. 57 (1993) 450–454.
265M. NARAT: Production of Antibodies in Chickens, Food Technol. Biotechnol. 41 (3) 259–267 (2003)
48. E. C. Y. LiChan, S. S. Lee, A. Kummer, E. M. Akita, J. Food
Biotechnol. 22 (1998) 179–195.
49. T. Murata, S. Saito, M. Sziozaki, R. Z. Lu, Y. Eto, M. Funa-
ba, M. Takahashi, K. Torii, Proceedings of the Society for Exp.
Biol. Med. 211 (1996) 100–107.
50. T. I. Rosol, C. L. Steinmeyer, L. K. McCaukey, J. I.
Merryman, J. R. Wermeister, A. Grone, M. T. Weckmann,
D. E. Swayne, C. C. Capen, Vet. Immunol. Immunopathol. 35
(1993) 321–337.
51. M. Shimizu, A. Watanabe, A. Tanaka, Biosci. Biotech. Bio-
chem. 59 (1995) 138–139.
52. H. Meisel, Biol. Chem. Hoppe-Seyler, 375 (1994) 401–415.
53. C. S. Song, J. H. Yu, D. H. Bai, P. Y. Hester, K. H. Kim, J.
Immunol. 135 (1985) 3354–3359.
54. A. Hassl, H. Aspock, H. Flamm, Zbl. Bact. Hyg. A, 267
(1987) 247–253.
55. S. A. Goueli, J. Hanten, A. Davis, K. Ahmed, Biochem. Int.
21 (1990) 685–694.
56. U. S. Kunz, A. Pospichil, M. F. Paccaud, J. Vet. Med. 38
(1991) 292–298.
57. D. H. Du Plessis, W. Van Wyngaardt, M. Romito, M. Du
Plessis, S. Maree, Onderstepoort J. Vet. Res. 66 (1999) 25–28.
58. A. Cipolla, J. Cordeviola, H. Terzolo, G. Combessies, J. Bar-
don, N. Ramon, A. Martinez, D. Medina, C. Morsella, R.
Malena, ALTEX: Alternat. Zu Tierexperi. 18 (2001) 165–170.
59. F. De Ceuninck, F. Pastoureau, S. Agnellet, J. Bonnet, P.M.
Vanhoutte, J. Immunol. Methods, 252 (2001) 153–161.
60. M. Gross, J. Speck, DTW. Deutsche Tierarztliche Wo-
chenschrift, 103 (1996) 417–422.
61. J. A. Amaral, M. Tino De Franco, M. M. S. Carneiro-Sam-
paio, S. B. Carbonare, Res. Vet. Sci. 72 (2002) 229–234.
62. T. P. Vikinge, A. Askendal, B. Liedberg, T. Lindhal, P.
Tengvall, Biosens. Bioelectron. 13 (1998) 1257–1262.
63. E. Gutierrez Calzado, R. M. Garcia Garrido, R. Schade,
ATLA Altern. Lab. Anim. 29 (2001) 717–726.
64. N. Cuceanu, C. Constantinescu, E. Ioni, Arch. Roumaines
Path. Exp. Microbiol. 50 (1991) 215–222.
65. V. Sriram, C. E. Jebaraj, G. Yogeeswaran, Indian J. Exp.
Biol. 37 (1999) 639–649.
66. S. B. Carroll, B. D. Stollar, J. Biol. Chem. 258 (1983) 24–26.
67. M. Romito, G. J. Viljoen, D. H. Du Plessis, BioTechniques,
31 (2001) 674–675.
68. A. D. Di Leonardo, M. L. Marcante, F. Poggiali, E. Ham-
søikova, A. Venuti, Arch. Virol. 146 (2001) 117–125.
69. J.Yang, Z. Jin, Q. Yu, T. Yang, H. Wang, L. Liu, Chinese J.
Biotechnol. 13 (1997) 85–90.
70. J. C. Wallmann, C. Staak, E. Luge, J. Vet. Med. B, 37 (1990)
317–320.
71. E. M. Akita, E. C. Li-Chan, J. Dairy Sci. 81 (1998) 54–63.
72. S. C. Lee, K. N. Lee, D. G. Schwartzott, K. W. Jackson, W.
C. Tae, P. A. McKee, Prep. Biochem. Biotechnol. 27 (1997)
2272–237.
73. J. Fryer, J. Firca, J. Leventhal, B. Blondin, A. Malcolm, D.
Ivancic, R. Gandhi, A. Shah, W. Pao, M. Abecassis, D. Ka-
ufman, F. Stuart, B. Anderson, Xenotransplantation, 6 (1999)
98–109.
74. R. R. Marquardt, L. Z. Jin, J–W. Kim, L. Fang, A. A. Froh-
lich, S. K. Baidoo, FEMS Immunol. Med. Microbiol. 23 (1999)
283–288.
75. C. M. Almeida, M. M. Kanashiro, F. B. Rangel Filho, M. F.
Mata, T. L. Kipnis, W. D. da Silva, Vet. Res. 143 (1998)
579–584.
76. B. S. Thally, S. B. Carroll, Biotecnology, 8 (1990) 934–938.
77. D. J. Smith, W. F. King, R. Godiska, Infect. Immun. 69
(2001) 3135–3142.
78. H. Hatta, K. Tsuda, M. Ozeki, M. Kim, T. Yamamoto, S.
Otake, M. Hirasawa, J. Katz, N. K. Childers, S. M. Micha-
lek, Caries Res. 31 (1997) 268–274.
79. C. H. Kweon, B. J. Kweon, S. R. Woo, J. M. Kim, G. H.
Woo, D. H. Son, W. Hur, Y. S. Lee, J. Vet. Med. Sci. 62
(2000) 961–964.
80. S. B. Lee, Y. Mine, R. M. Stevenson, J. Agric. Food Chem.
48 (2000) 110–115.
81. G. Köhler, C. Milstein, Nature, 256 (1975) 495–497.
82. S. Nishinaka, T. Suzuki, H. Matsuda, M. Murata, J. Immu-
nol. Methods, 139 (1991) 217–222.
83. S. Nishinaka, H. Akiba, M. Nakamura, K. Suzuki, T. Su-
zuki, K. Tsubokura, H. Horiuchi, S. Furusawa, H. Matsu-
da, J. Vet. Med. Sci. 58 (1996) 1053–1056.
84. T. Koda, T. Shimosakoda, S. Nishinaka, H. Asaoka, H.
Nakaba, I. Tamura, H. Matsuda, Gan to Kagaku Ryoho,
Cancer Chemother. 21 (1994) 2771–2777.
85. H. Asaoka, H. Matsuda, J. Vet. Med. Sci. 56 (1994)
375–377.
86. K. Sasai, H. S. Lillehoj, H. Matsuda, W. P. Wergin, J. Para-
sitol. 82 (1996) 82–87.
87. K. Sasai, H. S. Lillehoj, A. Hemphill, H. Matsuda, Y Ha-
nioka, T. Fukata, E. Baba, A. Arakawa, J. Parasitol. 84
(1998) 654–656.
88. J. McCafferty, A. D. Griffiths, G. Winter, D. J. Chiswell,
Nature, 348 (1990) 552–554.
89. P. M. O’Brien, R. Aitken: Broadening the Impact of Anti-
body Phage Display Technology. In: Antibody Phage Di-
splay Methods and Protocols, P. M. O’Brien, R. Aitken
(Eds.), Humana Press, New Jersey (2002) pp. 73–86.
90. S. Tonegawa, Nature, 302 (1983) 575–581.
91. W. T. McCormack, C. B. Thompson, Gene. Dev. 4 (1990)
548–558.
92. E. L. Daves, J. S. Smith, C. R. Birkett, J. M. Manser, D. V.
Anderson-Dear, J. R. Young, J. Immunol. Methods, 186
(1995) 125–135.
93. H. I. Yamanaka, T. Inoue, O. Ikeda-Tanaka, J. Immunol.
157 (1996) 1156–1162.
94. N. Nakamura, Y. Aoki, H. Horiuchi, S. Furusawa, H. I.
Yamanaka, T. Kitamoto, H. Matsuda, Cytotechnology, 32
(2000) 191–198.
95. J. K. Kim, W. Min, H. S. Lillehoj, S. W. Kim, E. J. Sohn, K.
D. Song, J. Y. Han, Hybridoma, 20 (2001) 175–181.
96. W. Min, J. K. Kim, H. S. Lillehoj, E. J. Sohn, J. Y. Han, K.
D. Song, E. P. Lillehoj, Biotechnol. Lett. 23 (2001) 949–955.
97. K. D. Song, J. Y. Han, W. Min, H. S. Lillehoj, S. W. Kim, J.
K. Kim, J. Microbiol. 39 (2001) 49–55.
98. J. Andis-Widhopf, C. Rader, P. Steinberger, R. Fuller, C.
F. Barbas III, J. Immunol. Methods, 242 (2000) 159–181.
99. S. L. Morrison, M. S. Mohammed, L. A. Wims, R. Trinh,
R. Etches, Mol. Immunol. 38 (2002) 619–625.
100. M. S. Mohammed, S. L. Morrison, L. A. Wims, R. Trinh,
A. G. Wildeman, J. Bonselaar, R. J. Etches, Immunotechno-
logy, 4 (1998) 115–125.
101. M. Shimizu, Y. Miwa, K. Hashimoto, A. Goto, Biosc. Bio-
tech. Biochem. 57 (1993) 1445–1449.
102. M. Rejc, M. Narat, D. Ben~ina, F. Habe, Zb. Biotehni{ke
Fak. Univ. v Ljubljani. Kmetijstvo. Zootehnika, 76 (2000)
143–151.
103. D. Ben~ina, S. H. Kleven, M. G. Elfaki, A. Snoj, P. Dov~,
D. Dorrer, I. Russ, Avian Pathol. 23 (1994) 19–36.
104. M. Balls, A. M. van Zeller, M. Halder: Progress in the Re-
duction, Refinement and Replacement of Animal Experimenta-
tion, Elsevier, Amsterdam (2000).
266 M. NARAT: Production of Antibodies in Chickens, Food Technol. Biotechnol. 41 (3) 259–267 (2003)
Proizvodnja antitijela u pili}a
Sa`etak
Pili}i kao izvor potrebnih antitijela imaju neke prednosti, u usporedbi s drugim `ivo-
tinjama koje se koriste za njihovu proizvodnju, kao {to su velika produktivnost i osobita
prikladnost u njima proizvedenih antitijela za odre|ene dijagnosti~ke svrhe. Usprkos tome
{to je izvrstan pandan IgG-u sisavaca, IgY antitijela pili}a jo{ je uvijek nedovoljno isko-
ri{teni resurs. Mo`da je tome uzrok nedostatak informacija o mogu}nostima proizvodnje i
primjene IgY ili je njegovo kori{tenje ometano problemima ~uvanja pili}a i izolacijom IgY.
U radu je prikazan novi imunoafinitetni postupak izolacije kako bi se prevladali problemi
vezani za izolaciju IgY. Glavna je svrha ovoga rada informacija o razvoju i mogu}nostima
tijekom proizvodnje IgY pili}a. Sa`eto su prikazani poliklonalni, monoklonalni i rekombi-
nantni oblici IgY, do danas uspje{no proizvedeni, a i njihova primjena. Rad je doprinos
nastojanjima Europskog centra za pravovaljanost alternativnih postupaka (ECVAM), ~ija je
glavna svrha promocija i prihva}anje znanstvenih i regulacijskih alternativnih metoda,
va`nih za bioznanost, ~ime se smanjuje, profinjuje i nadomje{ta kori{tenje laboratorijskih
`ivotinja.
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